That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Mom Karen McGonigal, 53, died in May 2025 after taking an allegedly illegally administered dose of a semaglutide “jab.” The ...

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

Metsera, Inc. is at the center of a bidding war between Novo Nordisk and Pfizer, driving its stock up 20%. Learn more about ...

Hims & Hers ($HIMS) stock is drawing attention ahead of its Q3 earnings as the company expands into the booming weight-loss ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

A 67-year-old man presented with multiorgan failure, hypoglycaemia, cholestatic liver dysfunction, and two duodenal ulcers ...

Greater waist circumference reduction at week 20 linked to lower subsequent MACE risk for those receiving semaglutide.

Adults with obesity lose more weight with semaglutide than with placebo (a sham medication). However, the risk of unwanted events is probably higher than with placebo after 24 months. Semaglutide ...

In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by ...